ABSTRACT
Background and aims: Introduction: The COVID-19 pandemic has put the medical world at a critical juncture, we are facing a disease that is heterogeneous and has presented clinicians with the reality of multiorgan involvement, that can develop even months after the initial infection. Most patients are asymptomatic, but some develop severe organ dysfunction, and while the most common is respiratory failure, the CNS is also involved. Regarding demyelinating diseases associated to COVID- 19, there is limited data and case reports are few and far between. Methods: Case report. Results: Case presentation: A 33-year-old female patient with a history of systemic arterial hypertension and occasional alcoholism. She was admitted to the ER with weakness of the pelvic limbs and myalgias. Three weeks prior to admission, she developed asthenia, fever, adynamia, and dyspnea. PCR result for SARS-CoV2 positive. Upon admission, she presented weakness of the lower extremities, affecting her right body, was progressive, ascending, and made walking impossible, with hyperreflexia, dysesthesia, thoracic sensory level and loss of sphincter control, subsequently developing lagophthalmos, and dysarthria. CSF study, with mild mononuclear pleocytosis, oligoclonal bands were negative. MRI study showed demyelinating longitudinal myelitis, intramedullary lesions, hyperintense in T2, at the cervico-thoracic-lumbar levels. A PCR study for SARS-CoV2 in CSF was positive. Treatment was initiated with methylprednisolone boluses and IVIG. Conclusion: To acknowledge the possibility of COVID-19 associated demyelinating disease in any patient with previous SARS-CoV2 infection and loss of consciousness, ataxia, epilepsy, encephalitis, myelitis or optic neuritis, associated with this emergent disease.